BioCentury
ARTICLE | Company News

FDA approves Shire's Cuvitru

September 14, 2016 7:00 AM UTC

Shire plc (LSE:SHP; NASDAQ:SHPG) said FDA approved Cuvitru 20% subcutaneous immunoglobulin to treat primary immunodeficiency in patients aged two years and older. The company said it expects to launch Cuvitru "in the coming weeks."

Shire gained the treatment via its acquisition of Baxalta Inc. (see BioCentury, Jan. 18). ...